FN2 Earnings Intelligence

EW earnings history

Edwards Lifesciences Corporation (EW) quarterly earnings scorecards, market reactions, transcript intelligence, and historical context.

Earnings History

Estimate Beat Miss Match
EW EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 4 future estimate-only quarters. Q1 '24 estimate $0.64 Q1 '24 actual $0.66, beat Q2 '24 estimate $0.69 Q2 '24 actual $0.70, match Q3 '24 estimate $0.67 Q3 '24 actual $0.67, match Q2 '25 estimate $0.62 Q2 '25 actual $0.67, beat Q3 '25 estimate $0.60 Q3 '25 actual $0.67, beat Q4 '25 estimate $0.62 Q4 '25 actual $0.58, miss Q1 '26 estimate $0.73 Q1 '26 actual $0.78, beat Q2 '26 estimate $0.74 Q2 '26 actual $0.78, beat Q3 '26 estimate $0.74 Q4 '26 estimate $0.71 Q1 '27 estimate $0.84 Q2 '27 estimate $0.86
Show 1 more >
EW FY2026 Q2 · Calendar Q3 2026

Edwards Lifesciences Corporation

Edwards Lifesciences delivered a strong Q2 2026 with 12.5% YoY sales growth to $1.74 billion, beating EPS estimates by 5.0% and revenue estimates by 2.4%. The quarter was driven by broad adoption across TAVR, TMTT, and Surgical portfolios, with a competitor exit contributing to TAVR market share gains. Management raised full-year sales guidance from 8-10% to 10-11%, and the stock recovered 3.8% over subsequent sessions after an initial 1.5% dip, suggesting the market viewed the raise as well-supported despite tax and FX headwinds.

EPS surprise+5.0%
Market move-1.4%